Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

76.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,201
Open 76.85
Bid (Size) 77.75 (400)
Ask (Size) 79.00 (100)
Prev. Close 76.85
Today's Range 76.85 - 76.85
52wk Range 55.17 - 170.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
From GeneDx
Via Business Wire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Ark Invest's CEO kicked off the new trading week with a little shopping. 
Via The Motley Fool

Performance

YTD
-41.9%
-41.9%
1 Month
-18.9%
-18.9%
3 Month
-50.5%
-50.5%
6 Month
-39.0%
-39.0%
1 Year
-16.5%
-16.5%

More News

Read More
News headline image
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
From GeneDx
Via Business Wire
GeneDx Holdings Corp (NASDAQ:WGS) Reports Mixed Q4 2025 Results, Stock Falls Despite Strong 2026 Outlook ↗
Via Chartmill
News headline image
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
From GeneDx
Via Business Wire
News headline image
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally ↗
Via The Motley Fool
Topics Energy
News headline image
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell? ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
GeneDx to Participate in Upcoming Investor Conferences
From GeneDx
Via Business Wire
News headline image
GeneDx (WGS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
From GeneDx
Via Business Wire
News headline image
Power Solutions Stock Up 140% as $6.36 Million Exit Follows 62% Sales Surge ↗
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy ↗
Via The Motley Fool
News headline image
Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health
From GeneDx
Via Business Wire
News headline image
GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026
From GeneDx
Via Business Wire
News headline image
The Great Rotation: Small-Caps Stand Tall as AI Exhaustion Triggers Tech Rout
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Great Rotation of 2026: Why Wall Street is Abandoning Big Tech for Main Street Small Caps
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great AI Pivot: From Massive Build-Out to the Era of Operational ROI
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
The Great Rotation: Wall Street’s ‘Earnings Handoff’ Moves from Silicon Valley to Main Street
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
The Great Rotation: Small-Caps Set to Outpace ‘Magnificent 7’ in Historic Earnings Handoff
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
Via The Motley Fool

Frequently Asked Questions

Is GeneDx Holdings Corp. - Class A Common Stock publicly traded?
Yes, GeneDx Holdings Corp. - Class A Common Stock is publicly traded.
What exchange does GeneDx Holdings Corp. - Class A Common Stock trade on?
GeneDx Holdings Corp. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeneDx Holdings Corp. - Class A Common Stock?
The ticker symbol for GeneDx Holdings Corp. - Class A Common Stock is WGS on the Nasdaq Stock Market
What is the current price of GeneDx Holdings Corp. - Class A Common Stock?
The current price of GeneDx Holdings Corp. - Class A Common Stock is 76.85
When was GeneDx Holdings Corp. - Class A Common Stock last traded?
The last trade of GeneDx Holdings Corp. - Class A Common Stock was at 03/12/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.